Life Biosciences to Present at Longevity Leaders World Congress 2022

BOSTON, April 14, 2022  Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced that Jerry McLaughlin, Chief Executive Officer, will speak at the fourth annual Longevity Leaders World Congress being held on April 26-27, 2022, in London, UK.

Mr. McLaughlin will deliver a presentation on April 26 at 11:10 BST titled, “Targeting Mechanisms Underlying the Biology of Aging to Treat and Reverse Disease.”

“Life Biosciences is truly at the forefront of developing novel therapies based on exciting advances in age-related science,” says Mr. McLaughlin. “I’m delighted to have the opportunity to share more about our work and progress here at Life Biosciences and discuss ways to work with pioneers in the field to move our industry forward.”

The Longevity Leaders World Congress, hosted by LSX, brings the world’s most prominent regenerative medicine and longevity scientists together, presenting the new research, responsible drug development, novel therapies, and commercialization to target age-related diseases. Those interested in attending the conference may register here.

About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to discovering and developing novel therapies to improve the lives of people as they age. The company is focusing on three platforms targeting key mechanisms underlying aging biology: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Therapies developed within each platform have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.

Media
media@lifebiosciences.com

Investor Relations
Bill Sullivan
IR@lifebiosciences.com

Life Biosciences, Leading Developer of Therapeutics for Aging-Related Diseases, Completes $82 Million Series C Financing Round

Announces Bill Sullivan as Chief Financial Officer

Life Biosciences Receives Translational Research Funding from Alzheimer’s Drug Discovery Foundation

BOSTON, Sept. 28, 2021 — Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced translational research funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to support the development of chaperone-mediated autophagy (CMA) activators for the treatment of Alzheimer’s disease and other neurodegenerative diseases.

Chaperone-mediated autophagy removes unwanted soluble proteins from cells.  CMA activity declines with age due in part to decreased expression of LAMP2A, a key protein regulating CMA activity. The age-related decline of CMA leads to an accumulation of insoluble proteins that disrupt cellular function in age-related diseases such as Alzheimer’s disease.

In groundbreaking work published in the peer-reviewed journal Cell in April 2021, Professor at the Albert Einstein College of Medicine and Life Biosciences founder scientist Ana Maria Cuervo, MD, PhD demonstrated the benefit of the CMA-activator platform in two mouse models of Alzheimer’s disease. In both models, oral doses of CMA-activator compounds led to improvements in memory, depression, and anxiety. Life Biosciences has an exclusive license from Albert Einstein College of Medicine for this underlying technology and will continue this research by evaluating CMA-activator compounds for key early attributes needed in Alzheimer’s disease drug development.

“We are pleased to have received this translational research funding from the ADDF, which further validates the potential of our CMA platform to treat devastating diseases such as Alzheimer’s,” said Jerry McLaughlin, Chief Executive Officer of Life Biosciences. “Our preclinical work to date has demonstrated that CMA activation may be a viable therapeutic strategy in halting the progression of age-related neurodegenerative disorders and ultimately increase healthy human lifespan. We look forward to advancing this platform towards the clinic with the support of the ADDF.”

“Life Biosciences’ innovative pathway holds exciting promise for the potential treatment and prevention of Alzheimer’s disease,” said Howard Fillit, MD, Founding Executive Director and Chief Science Officer of the ADDF. “After substantial scientific review, we believe that CMA could offer a unique approach to Alzheimer’s disease, and we look forward to partnering with Life Biosciences as it advances its important research towards the clinic.”

About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to developing novel therapies to extend healthy human lifespan. The Company is focusing on three platforms targeting key mechanisms underlying aging biology: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Therapies developed within each platform have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.

About the Alzheimer’s Drug Discovery Foundation
Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer’s disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer’s and related dementias, employing a venture philanthropy model to support research in academia and the biotech industry. Through the generosity of its donors, the ADDF has awarded more than $168 million to fund over 650 Alzheimer’s drug discovery and biomarker programs and clinical trials in 19 countries. To learn more, please visit: http://www.alzdiscovery.org/.

Media Contact
Maggie Farrand
media@lifebiosciences.com

Life Biosciences Appoints Seasoned Biopharma Executive Jerry McLaughlin as CEO

Dr. Mehmood Khan to remain Executive Chairman

BOSTON, July 1, 2021 Life Biosciences, a pioneering life sciences company targeting the biology of aging, today announced that the Company’s Board of Directors has appointed Jerry McLaughlin as Chief Executive Officer and a member of the Board. Dr. Mehmood Khan will serve as Executive Chairman of the Board.

“I welcome Jerry to the Life Biosciences team at this exciting time for the company,” said Life Biosciences co-founder and Board member David Sinclair, PhD, AO. “Jerry’s extensive experience leading both public and private companies through clinical development and financing will be an invaluable asset as we advance our multiple leading programs. I would also like to thank Dr. Khan for leading Life Biosciences and achieving important milestones over the past few years, including progressing our three platforms toward the clinic. Mehmood’s continued guidance as Executive Chairman, along with Jerry’s stewardship as CEO, will position Life Biosciences for lasting success.”

“It has been a privilege to serve as Life Biosciences’ CEO, and I am proud of the work we have accomplished together,” said Dr. Khan. “With Jerry’s strong track record of operational excellence, innovation, and delivering results, I am confident he is the ideal person to lead Life Biosciences through its next pivotal phase. I look forward to working with him as Executive Chairman.”

Mr. McLaughlin has over 30 years of experience in the biopharmaceutical industry and has been involved in the discovery, clinical development, and global commercialization of more than a dozen FDA-approved drugs with multiple successful exits. Most recently, he was President and CEO for Neos Therapeutics, Inc., a commercial stage pharmaceutical company. Before that, Mr. McLaughlin served as President and CEO of AgeneBio, Inc., a clinical-stage private biopharma company developing therapies for neurological and psychiatric diseases. Earlier, he held the role of Senior Vice President & Chief Commercial Officer at NuPathe Inc., acquired by Teva Pharmaceuticals in 2014. Mr. McLaughlin began his career at Merck and was extensively involved in multiple blockbuster product launches. He holds a BA in economics from Dickinson College and an MBA from the Villanova School of Business.

“I am thrilled to join Life Biosciences as the company works to advance its first programs toward the clinic,” said Mr. McLaughlin. “Having led companies for over a decade that address neurological and psychological conditions and deficits, I am well versed with the negative impacts of aging on the brain and body. Life Biosciences’ groundbreaking work to address and treat the underlying biology of aging has the potential to lead the next generation of therapies for a growing population that faces increasing challenges from diseases that correlate tightly with growing older.”

Dr. Khan will become CEO at a newly founded global non-profit organization focused on funding research on therapies that address aging biology and extend human healthspan. Dr. Khan’s new role is complementary to Life Biosciences’ research and development work, and he will continue to support the Company as Executive Chairman. Additional details relating to Dr. Khan’s new role will be announced later this year.

About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to developing novel therapies to extend healthy human lifespan. The Company is focusing on three platforms targeting key mechanisms underlying aging biology: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Therapies developed within each platform have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.

Media Contact
Maggie Farrand
media@lifebiosciences.com

Life Biosciences Announces Publication in Cell Demonstrating Therapeutic Benefit of Chaperone-Mediated Autophagy Activators in Alzheimer’s Disease Models

BOSTON, April 22, 2021 Life Biosciences, a pioneering life sciences company targeting the biology of aging, today announced the publication of preclinical research demonstrating clinical benefit of its chaperone-mediated autophagy activator platform in mice models of Alzheimer’s disease. The article, titled Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome by Bourdenx et al., was published online in the peer-reviewed journal Cell on April 22, 2021.

Chaperone-mediated autophagy (CMA) controls the levels of soluble proteins in cells. It has been proposed that the age-related decline of CMA leads to an increased concentration of insoluble proteins that may play a role in the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease. This study demonstrated that the upregulation of CMA with one of Life Biosciences’ tool oral compounds significantly improved neurologic function and decreased the accumulation of insoluble protein aggregates in two different mouse models of Alzheimer’s disease, even after the onset of neurologic dysfunction.

“The publication of this preclinical study validates our CMA platform and demonstrates that an age-related decline in CMA activity may contribute to the pathogenesis of Alzheimer’s disease,” said Joan Mannick, MD, Head of Research and Development at Life Biosciences. “As we look ahead, we anticipate advancing our platform of CMA activating candidates towards the clinic for the potential treatment of aging-related diseases including neurodegenerative diseases.”

Ana Maria Cuervo, MD, PhD, a Life Biosciences founder scientist and Professor and Co-Director of the Institute for Aging Research at the Albert Einstein College of Medicine, commented, “The results of this study identify a direct contribution of CMA to the maintenance of the neuronal proteome in vivo in physiological and pathological conditions. Additionally, this paper provides evidence of the potential value of CMA activation as a therapeutic strategy for age-related neurodegenerative disorders. We look forward to progressing the clinical development of our compounds that activate CMA and believe that this new approach has the potential to prevent the buildup of insoluble proteins that underlie neurologic dysfunction.”

Life Biosciences has in-licensed the intellectual property related to targeting of CMA from Albert Einstein College of Medicine.

About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to developing novel therapies to extend healthy human lifespan. The Company is focusing on three platforms targeting key mechanisms underlying aging biology: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Therapies developed within each platform have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.

Media Contact
Maggie Farrand
media@lifebiosciences.com

Investor Relations Contact
Stern Investor Relations
Alexander Lobo
alex.lobo@sternir.com

Life Biosciences to Present at 5th Stanford Drug Discovery Symposium

BOSTON, April 14, 2021 — Life Biosciences, a pioneering life sciences company targeting the biology of aging, today announced that Joan Mannick, MD, Head of Research and Development, will participate in the 5th Stanford Drug Discovery Symposium (SDDS 2021) being held virtually on April 19-20, 2021.

5th Stanford Drug Discovery Symposium (SDDS 2021)
Session VIII: Discovery Research II
Presentation: Targeting the Biology of Aging to Prevent or Treat Aging-related Diseases
Moderators: Marc Tessier-Lavigne, PhD, and Kuldev Singh, MD
Tuesday, April 20, 2021
2:45pm ET / 11:45am PT

The Stanford Drug Discovery Symposium takes advantage of the collective experience and expertise of participants to cover a broad range of policy, research, and venture topics. This symposium provides an invaluable forum for interdisciplinary exchange at the forefront of drug research. Those interested in attending the virtual symposium may register here.

About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to developing novel therapies to extend healthy human lifespan. The Company is focusing on three platforms targeting key mechanisms underlying aging biology: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Therapies developed within each platform have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.

Media Contact
Maggie Farrand
media@lifebiosciences.com

Investor Relations Contact
Stern Investor Relations
Alexander Lobo
alex.lobo@sternir.com

Life Biosciences Announces Pioneering Research in Nature Describing New Mechanisms for Reversing Age-Related Disease

BOSTON, Feb. 18, 2021 — Life Biosciences, a pioneering life sciences company targeting the biology of aging, has in-licensed intellectual property related to scientific findings recently described in two publications in the journal Nature. The publications, based on research conducted in animal models, report that therapies targeting the biology of aging have the potential to not only slow the progression but also to reverse aging-related disease. Life Biosciences intends to develop new therapies for aging-related conditions.

“These two studies open a new frontier in biotechnology and medicine,” says Mehmood Khan, MD, Chief Executive Officer of Life Biosciences. “They pave the way for the development of groundbreaking treatments to restore the function of aging organ systems and thereby allow people to live healthier longer.”

The first article reports on studies led by David Sinclair, PhD, AO, a co-founder of Life Biosciences, and his colleagues at Harvard Medical School, Massachusetts Eye and Ear, Massachusetts General Hospital, University of California Los Angeles, and Yale School of Medicine. In this study, conducted in cell lines and in animal models, the researchers rejuvenated damaged or aged cells in the eye with a gene therapy that induced expression of three of the Yamanaka factor proteins. This gene therapy allowed nerves in the eye to regrow after injury and safely restored vision, both in old mice and in a mouse model of glaucoma. The full article, titled “Reprogramming to recover youthful epigenetic information and restore vision,” is available through the Nature website (https://doi.org/10.1038/s41586-020-2975-4). The license held by Life Biosciences subsidiary, Iduna Therapeutics, from Harvard University covers a patented gene therapy system for the expression of specific factors known to induce pluripotency and rejuvenation.

“The study shows for the first time that it may be possible to wind the clock back in complex tissues to restore youthful biological functions such as vision,” said Sinclair. “It is promising research in terms of how we address aging-related diseases, including diseases such as glaucoma, which affect many patients later in life.”

The second article reports on studies led by Ana Maria Cuervo, MD, PhD, a Life Biosciences founder scientist and member of the National Academy of Sciences. Dr. Cuervo and her colleagues at Albert Einstein College of Medicine and the University of Colorado Denver reported that the diminished ability of old mouse and human hematopoietic stem cells (HSCs) to produce new blood cells is correlated with a decline in a process called chaperone-mediated autophagy (CMA). CMA breaks down unwanted proteins in cells and recycles them into nutrients. When CMA was activated in the hematopoietic stem cells of geriatric mice, either genetically or by treatment with a small molecule, the old stem cells regained the capacity of young stem cells to generate new blood cells. The findings indicate that therapies that activate CMA have the potential to restore the function of aging hematopoietic stem cells and improve immune function. Life Biosciences has in-licensed the intellectual property related to targeting of CMA from Albert Einstein College of Medicine. The full article, titled “Chaperone-mediated autophagy sustains haematopoietic stem-cell function,” is available through the Nature website (https://doi.org/10.1038/s41586-020-03129-z).

“By activating chaperone-mediated autophagy, we are able to restore the functionality of hematopoietic stem cells in both old mice and older humans, which has very important therapeutic implications,” said Cuervo. “We are looking forward to further investigating how we can put chaperone-mediated autophagy to use in restoring the vitality of aging cells in older people.”

About Life Biosciences
Founded in 2017 and headquartered in Boston, Life Biosciences brings scientists together from the world’s preeminent research and academic institutions into a discovery, development, and commercialization ecosystem dedicated to extending the healthy human lifespan. We are pursuing clinical therapies across multiple molecular pathways that regulate the biology of aging. This means our therapies each have the potential to address multiple age-related diseases that impact longevity far upstream from conventional medicine. www.lifebiosciences.com

Media Contact
Maggie Farrand
media@lifebiosciences.com

Life Biosciences Appoints Joan Mannick, MD, to Lead its Research and Development

Expert on aging will focus on R&D pipeline and clinical preparations

BOSTON, Feb. 1, 2021 —Life Biosciences, a pioneering life sciences company targeting aging biology, announced today the appointment of Joan Mannick, MD, as Head of Research and Development. With more than 20 years of experience, Dr. Mannick will direct and manage the company’s portfolio of R&D operations.

“We are excited to welcome Dr. Mannick as our Head of R&D,” said Mehmood Khan, MD, Chief Executive Officer, Life Biosciences. “Joan’s expertise aligns so closely with our vision of pursuing therapies for age-related diseases by targeting the biological causes of aging, and I’m confident she will help us take Life Biosciences to the next level.”

Dr. Mannick joins Life Biosciences from Adicet Bio, formerly resTORbio, where she served as Co-Founder and Chief Medical Officer and led R&D efforts. Before that, she served as Executive Director of the New Indications Discovery Unit at Novartis Institutes of Biomedical Research, where she led their clinical-stage program targeting aging biology as a new way to treat aging-related conditions. Prior to joining Novartis, Dr. Mannick was Medical Director at Genzyme Corporation working in multiple therapeutic areas including leading an investigator-sponsored program for an early stage oncology product. She has served as faculty member at Harvard Medical School and University of Massachusetts Medical School. She received her AB from Harvard College and MD from Harvard Medical School. She completed her residency at Brigham and Women’s Hospital, followed by an infectious diseases fellowship as part of the Harvard Combined Infectious Diseases Program.

“I am thrilled to join Life Biosciences because I think it has in-licensed the most exciting programs of any company in the aging field,” said Dr. Mannick. “With truly inspiring science and an incredibly talented team of world-leading researchers, Life Biosciences has huge potential to change the course of aging and age-related diseases, and I am honored to now be a part of it.”

About Life Biosciences
Founded in 2017 and headquartered in Boston, Life Biosciences brings scientists together from the world’s preeminent research and academic institutions into a discovery, development, and commercialization ecosystem dedicated to extending the healthy human lifespan. We are pursuing clinical therapies across multiple molecular pathways that regulate the biology of aging. This means our therapies each have the potential to address multiple age-related diseases that impact longevity far upstream from conventional medicine. www.lifebiosciences.com

Media Contact
Maggie Farrand
media@lifebiosciences.com

Life Biosciences Strengthens Executive Leadership Team with Addition of Amit Shashank as General Counsel

BOSTON, May 13, 2019 — Life Biosciences announced today that Amit Shashank is joining the company as General Counsel.  Mr. Shashank is a strategically-oriented global leader, with more than twenty years of international experience in technology and business services organizations – both private and public – and demonstrated expertise that spans complex mergers and acquisitions, commercial transactions, and all phases of corporation financings including initial public offerings (IPOs).  Amit has broad legal and compliance experience across a number of industries including healthcare, financial services, telecommunications and semiconductors.

“I am thrilled to be joining Life Biosciences at this moment in the company’s development,” said Mr. Shashank.  “Life Biosciences has both a sweeping mission – to bring extended health spans to everyone in the world – and a brilliant research team to accomplish it.  The company’s pending research and its focus on the underlying pathways of aging offer a paradigm shift from the existing model of drug discovery and development.”

“We couldn’t be more excited to welcome Amit to the team,” said Mehmood Khan, the Chief Executive Officer of Life Biosciences.  “At a company like ours conducting breakthrough research that will require complex regulatory approvals and is actively pursuing strategic alliances and other business opportunities, the role of General Counsel is of critical importance.  I can’t think of anyone more perfectly suited to this role than Amit.”

Most recently, Mr. Shashank served as Executive Vice President, General Counsel and Secretary of Aricent, a global R&D engineering and design powerhouse with over 10,000 employees.  In 2018, Mr. Shashank was instrumental in supporting KKR & Co. in the sale of Aricent to Altran Technologies for $2.0 billion.  Prior to Aricent, Amit served as Executive Vice President, General Counsel, Chief Compliance Officer and Secretary at ExlService Holdings, Inc., an operations management and analytics company with more than 20,000 employees globally, where he led the IPO and NASDAQ listing of the company.

Mr. Shashank began his career at Shearman and Sterling LLP after graduating from The University of Michigan Law School, where he was editor-in-chief of the Michigan Journal of International Law.  Amit is also a Rhodes Scholar.

–       Life Biosciences Overview   –

Life Biosciences is dedicated to tackling eight pathways of age-related decline (ARD) as the cause of the systemic breakdown of the body, rather than a series of isolated symptoms, events and conditions. The company brings together the world’s leading scientists and researchers to increase health spans and reduce disease for everyone, including companion animals.

Life Biosciences has established Daughter companies around the world to independently and collaboratively attack these pathways through pioneering research and product development. Its Daughter companies have access to Life Biosciences’ centralized resources, including experienced management and drug development expertise, access to LifeLabs, a state-of-the-art research facility in Cambridge, Massachusetts, and the full resources of Lua, a HIPAA-compliant communications platform which also provides data analytics to support and connect Life Biosciences’ laboratory and teams across the United States, Europe, Asia, and Australia.

For more information on Life Biosciences, please visit www.lifebiosciences.com.

Press Contact: 
media@lifebiosciences.com

Dr. Mehmood Khan Named CEO of Life Biosciences

PepsiCo’s Former Vice Chairman and Chief Scientific Officer, Former President of Global R&D, Takeda Pharmaceuticals, to Lead Longevity Biotech

BOSTON, March 4, 2019 — Life Biosciences Inc. today announced Dr. Mehmood Khan, former PepsiCo Vice Chairman and Chief Scientific Officer, is incoming Chief Executive Officer and member of its board of directors. Dr. Khan will lead the Boston-based biotech company, which has raised more than $75 million to pursue the eight pathways of age-related decline (ARD). The company was co-founded by former hedge fund manager and global institutional investor, Tristan Edwards and David Sinclair PhD, AO, Professor in the Department of Genetics at Harvard Medical School and co-Director of the Paul F. Glenn Center for the Biological Mechanisms of Aging.

“We are proud and humbled by Mehmood’s decision to join and lead our company,” said Edwards, former Chief Executive Officer of Life Biosciences, who remains President and assumes the position of Chief Investment Officer. “He brings a remarkable depth of business and scientific expertise to our team, and is exactly the right leader for Life Biosciences as we enter our next phase of growth.  His contributions to our work will be immense.”

In his prior role with PepsiCo, a company which generated more than $64 billion in revenue in 2018, Dr. Khan led research and development efforts and oversaw PepsiCo’s global sustainability initiatives. He was challenged to create breakthrough innovations across the food and beverages category, including helping to drive growth for its nutritious offerings across the portfolio.

“Tristan and David have done a remarkable job establishing Life Biosciences as the leader in the longevity space,” said Khan. “Under their guidance, the company has grown tremendously and has already made much progress in tackling the issues of age-related decline. I’m excited to now work beside them in this next phase, continuing to grow and advance Life Biosciences.”

Prior to joining PepsiCo, Dr. Khan was President of Takeda Global Research & Development Center, overseeing Takeda’s worldwide R&D efforts. Before this, he was a faculty member at the Mayo Clinic and Mayo Medical School where he served as Director of the Diabetes, Endocrine and Nutritional Trials Unit in the endocrinology division. Dr. Khan also spent nine years leading programs in diabetes, endocrinology, metabolism and nutrition for the Hennepin County Medical Center in Minneapolis.

Life Biosciences Overview –

Life Biosciences is dedicated to tackling the eight pathways of age-related decline (ARD) as the cause of the systemic breakdown of the body, rather than a series of isolated symptoms, events and conditions. The company brings together the world’s leading scientists and researchers to increase health spans and reduce disease for everyone, including companion animals.

When Edwards co-founded Life Biosciences in 2017, he developed its innovative structure as Chapter Two in his life, after a highly successful career as a global institutional investor, working across all asset classes.  There are six Daughter companies working independently and together within the Life Biosciences research environment.

The company also recently announced a significant investment in Prana, a publicly traded Australian biotech company, the closing of its Series B round of investment, and the acquisition of Lua, Life Biosciences’ HIPAA-compliant medical technology platform.  Life Biosciences provides Daughter companies with the resources required to maximize human potential, including experienced management, drug development experience, and a 24,000-square-foot, state-of-the-art vivarium, robotics and drug screening facility in Cambridge, Mass, in addition to laboratories and offices on four continents connected by Life Lua’s communications and data analysis platform.

Founded in 2017 by David Sinclair, PhD, AO, and Tristan Edwards, Life Biosciences addresses the eight pathways of age-related decline (ARD) as a systemic breakdown of the body, not a series of isolated symptoms and conditions. It has established Daughter companies around the world to independently and collaboratively attack these pathways through pioneering research and product development. The company provides Daughter companies with the full resources of Lua’s data communications and analytics platform; LifeLab, its 24,000-square-foot, state-of-the-art research facility that includes a vivarium, robotics, and drug screening capabilities. Life Biosciences seeks to increase healthspans for everyone, including companion animals.

For more information on Life Biosciences, please visit www.lifebiosciences.com
Press Contact:
media@lifebiosciences.com 
susanm@lifebiosciences.com 
erinf@lifebiosciences.com